ACHFF.US Arch Biopartners Inc

Healthcare Biotechnology USA Stocks
0.6600 USD
Close of Nov 13, 2026
0.2880 1.02
Market cap
USD 44.8M
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.

Is ACHFF.US undervalued?

Graham number

The Graham number of Arch Biopartners Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Arch Biopartners Inc fundamental analysis

No fundamental analysis for Arch Biopartners Inc yet.

Arch Biopartners Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Arch Biopartners Inc

Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops CKD Platform, t…

Full company profile